Equities

Lexaria Bioscience Corp

LEXX:NAQ

Lexaria Bioscience Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)3.15
  • Today's Change-0.07 / -2.17%
  • Shares traded130.66k
  • 1 Year change+246.19%
  • Beta1.0436
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy0
Outperform2
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The 3 analysts offering 12 month price targets for Lexaria Bioscience Corp have a median target of 10.00, with a high estimate of 12.00 and a low estimate of 8.00. The median estimate represents a 217.46% increase from the last price of 3.15.
High281.0%12.00
Med217.5%10.00
Low154.0%8.00

Earnings history & estimates in USD

On Jul 12, 2024, Lexaria Bioscience Corp reported 3rd quarter 2024 losses of -0.13 per share.
The next earnings announcement is expected on Nov 19, 2024.
Average growth rate-0.90%
Lexaria Bioscience Corp reported annual 2023 losses of -1.01 per share on Nov 20, 2023.
Average growth rate-583.56%
More ▼

Revenue history & estimates in USD

Lexaria Bioscience Corp had 3rd quarter 2024 revenues of 84.00k. This missed the 150.00k consensus estimate of the 2 analysts following the company. This was 9.68% below the prior year's 3rd quarter results.
Average growth rate-35.07%
Lexaria Bioscience Corp had revenues for the full year 2023 of 226.00k. This was 11.37% below the prior year's results.
Average growth rate+21.08%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.